UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):    June 17, 2008

_________________________

Auriga Laboratories, Inc.

(Exact name of registrant as specified in its charter)

_________________________

Delaware	000-26013	84-1334687
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5284 Adolfo Road, Camarillo, California 93012

(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (805) 437-7200

 (Former name or former address, if changed since last report)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 1 – REGISTRANT’S BUSINESS AND OPERATIONS

Item 1.02  Termination of a Material Definitive Agreement.

On June 17, 2008, Auriga Laboratories, Inc. (the “Company”) notified Dutchess Private Equities Fund, Ltd. (“Dutchess”) of termination of the Investment Agreement between the parties, effective June 30, 2008.

As disclosed in the Company’s Form 8-K filed on December 19, 2007, the Company and Dutchess entered into the Investment Agreement and a Registration Rights Agreement as of December 17, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Auriga Laboratories, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 18, 2008	AURIGA LABORATORIES, INC.
	By: /s/ Frank Greico
	Frank Greico
	Chief Financial Officer